Anti-malarial market and policy surveys in sub-Saharan Africa
<p>Abstract</p> <p>At a recent meeting (Sept 18, 2009) in which reasons for the limited access to artemisinin-based combination therapy (ACT) in sub-Saharan Africa were discussed, policy and market surveys on anti-malarial drug availability and accessibility in Burundi and Sierra L...
Main Authors: | Sevcsik Ann-Marie, Boakye Isaac, Amuasi John, Diap Graciela, Pecoul Bernard |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2010-04-01
|
Series: | Malaria Journal |
Online Access: | http://www.dndi.org/ |
Similar Items
-
Access to artesunate-amodiaquine, quinine and other anti-malarials: policy and markets in Burundi
by: Dismas Baza, et al.
Published: (2011-02-01) -
Access to artemisinin-combination therapy (ACT) and other anti-malarials: national policy and markets in Sierra Leone.
by: John H Amuasi, et al.
Published: (2012-01-01) -
New, improved treatments for Chagas disease: from the R&D pipeline to the patients.
by: Isabela Ribeiro, et al.
Published: (2009-01-01) -
Time to scale up molecular surveillance for anti-malarial drug resistance in sub-saharan Africa
by: Christian Nsanzabana
Published: (2021-10-01) -
Deployment and utilization of next-generation sequencing of Plasmodium falciparum to guide anti-malarial drug policy decisions in sub-Saharan Africa: opportunities and challenges
by: Deus S. Ishengoma, et al.
Published: (2019-09-01)